Recros Medica, Inc., a San Diego, CA-based an aesthetic company focused on developing medical devices to reduce skin laxity and improve focal contouring, closed a $14m Series A financing.
Led by Tom Albright, president and CEO, Recros is an aesthetic company focused on developing medical devices to reduce skin laxity and improve focal contouring via its Nuvellus® Focal Contouring system. The Nuvellus® platform, based on proprietary rotational fractional resection technology, may offer a novel procedure that produces results from a single treatment. Nearly 100 subjects have been treated in 4 IRB-approved clinical trials and the company is currently planning a pivotal clinical study.
Recros is also developing Nuvellus® to facilitate autologous dermal transfer, as a natural alternative to commercial dermal fillers.
Pharmaceutical and medical device company Haohai Healthcare Holdings Co., Limited of Shanghai, China was the sole investor.
These funds will be used to continue the development of the Nuvellus® Focal Contouring system, conduct a pivotal clinical study and achieve FDA clearance to commercialize the system in the U.S.